Introduction: Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors are the latest class of anti-hyperglycaemic agents which reduce blood glucose by increasing urinary glucose excretion.
Aims: 1) To assess the metabolic and haemodynamic changes associated with SGLT-2 inhibitors in patients attending Sligo University Hospital (SUH) Ireland.
2) To enhance prescriber awareness across disciplines regarding the metabolic and haemodynamic benefits in addition to improving cardio-renal outcomes as demonstrated in the EMPAREG, CANVAS & DECLARE meta-analysis
Methodology: After screening for eligibility, we selected 98 patients prescribed SGLT2-Inhibitors between January 2014 to December 2018. We excluded those with incomplete data and whose medications were stopped during the initial 6-month period. Retrospective data was collected from Medical Charts, NIMIS®, IPMS® and ProWellness IT Diabetes Database®. Data was collected at Baseline and at 6 months after the start of SGLT-2i for body weight, blood pressure, HbA1c and lipid profile.
Mean HbA1c was 8.89(1.44) % at baseline which dropped significantly to 8.04(1.22) % at 6 months. A similar highly significant change was observed when comparing weights at baseline and 6 months: 95.49(20.5) kg to 93.29(19.6)kg. Blood pressure changes were remarkable but there was only a modest improvement of HDL with no significant changes in Total Cholesterol, LDL and Triglycerides.
|Baseline Characteristics (n=98)|
|Age (Years)||62.13 ± (12.29)|
|DM Duration (Years)||129|
|Median Treatment (Years)||2|
|Changes in The Examined Variables After 6 Months Of Starting SGLT2-Inhibitors|
|Systolic Blood Pressure (mmHg)||143.75||135.41||<0.0001|
|Diastolic Blood Pressure (mmHg)||80.60||77.96||<0.0001|
Conclusion: The use of SGLT-2 Inhibitors in SUH was associated with significant metabolic and haemodynamic improvements which were better than expected when compared with those documented in large volume trials